Aussie peanut drug on FDA fast track

Posted 6 August 2026 PM

Melbourne biotech Aravax has been given US FDA Fast Track designation for its peanut allergy immunotherapy, PVX108.

The therapy uses seven proprietary synthesised peptides designed to retrain the immune system to tolerate peanut, while avoiding the acute allergic reactions associated with whole-protein immunotherapies, Aravax says.

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here